Form 4: Polaris Entities Boost Stake in Camp4 Therapeutics via Private Placement

Polaris Management Co. VII and related entities acquired over 1.3 million shares of Camp4 Therapeutics common stock in a private placement.

Summary

• Polaris Management Co. VII, L.L.C. and several affiliated entities, including Polaris Partners VII, L.P. and Polaris Entrepreneurs' Fund VII, L.P., acquired common stock of Camp4 Therapeutics Corp.
• The transactions occurred on September 11, 2025, as part of a private placement under a Securities Purchase Agreement dated September 9, 2025.
• Polaris Partners VII, L.P. purchased 1,221,721 shares of common stock at a price of $1.53 per share.
• Polaris Entrepreneurs' Fund VII, L.P. purchased 85,468 shares of common stock at a price of $1.53 per share.
• Following these transactions, Polaris Management Co. VII, L.L.C. indirectly beneficially owns 2,825,500 shares through Polaris Partners VII, L.P. and 197,661 shares through Polaris Entrepreneurs' Fund VII, L.P.
• Polaris Partners GP X, L.L.C. indirectly beneficially owns 909,090 shares through Polaris Partners X, L.P.
• The reporting persons, including directors Amy W. Schulman and Brian Chee, are associated with these Polaris entities and are considered 10% owners of Camp4 Therapeutics Corp.

Sentiment

Score: 8

Explanation: The significant insider buying by multiple Polaris entities, including those associated with company directors, indicates strong confidence in the company's prospects and is generally viewed very positively by the market.

Positives

• Significant insider buying by Polaris entities, including those associated with board members, signals strong confidence in Camp4 Therapeutics' future prospects.
• The private placement provides capital to Camp4 Therapeutics, which can be used for operations, research, and development.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the significant insider investment suggests a positive outlook from key stakeholders.

Management Comments

• The acquisition of shares by Polaris entities, whose managing members include Camp4 Therapeutics directors Amy Schulman and Brian Chee, demonstrates a strong vote of confidence in the company's strategic direction and future value.

Industry Context

Insider buying, especially by significant shareholders and directors, is often interpreted by the market as a positive signal, indicating that those with intimate knowledge of the company believe its stock is undervalued or poised for growth. This action aligns with a broader trend of strategic investments in promising biotechnology firms.

Related Party Transactions

• The transactions involve Polaris entities, which are 10% owners and have directors (Amir Nashat, Amy Schulman, Brian Chee) associated with their management, making these related-party transactions.

Stakeholder Impact

• Shareholders: Increased insider ownership may instill confidence and potentially lead to positive share price movement.
• Company: The private placement provides additional capital, strengthening the company's financial position for ongoing operations and strategic initiatives.

Key Dates

Recommendation

The substantial insider buying by Polaris entities, including those with board representation, at a fixed price of $1.53 per share, signals strong conviction from well-informed parties. This action suggests that insiders believe the company's stock is undervalued or has significant upside potential, making it an attractive opportunity for investors.

Keywords

Camp4 Therapeutics, CAMP, Polaris, Insider Buying, Private Placement, Common Stock, Equity Investment, Biotechnology